FOR PATIENTS
For Patients

ABOUT OUR TRIALS

Lighting the way

Clinical trials of lerapolturev (formerly PVSRIPO)

Several clinical trials of lerapolturev are now open for patients to join. Clinical trials are research studies to help find out if a potential treatment is safe and effective for a specific disease. If you join a clinical trial, the trial team will watch over your health carefully.

To join a clinical trial, you will have to meet many specific requirements regarding your health, the type of cancer you have, and other treatments you may have received. Each of our clinical trials has an information sheet with some of these requirements. If you think one of these clinical trials might be right for you, a family member, or a friend, you can download the information sheet and show it to your oncology team. They can help determine whether you meet these requirements and if this clinical trial may be right for you.

Glioblastoma
Clinical trial in glioblastoma that has returned after other treatment (LUMINOS-101)

Glioblastoma is a type of brain cancer. This clinical trial is for people with glioblastoma who previously received treatment with surgery, radiation therapy, and chemotherapy if appropriate. All patients in this clinical trial will receive lerapolturev followed by another immunotherapy called pembrolizumab (Keytruda®).

Download PDF

Download the information sheet for more information about this trial that you can show to your oncology team

Find out more
Melanoma
Clinical trial in advanced melanoma skin cancer that has returned after certain other treatments (LUMINOS-102)

LUMINOS-102 is for patients with melanoma (an aggressive type of skin cancer) for whom surgery to remove the cancer is not possible and who have already received another type of medication called a checkpoint inhibitor. Depending on the genetics of the cancer, other previous treatment may be required. Patients whose cancer has spread to the brain (brain metastases) may be eligible if the cancer in the brain is stable.

Patients in this clinical trial may receive either lerapolturev alone or lerapolturev together with a checkpoint inhibitor, either pembrolizumab (Keytruda®) or nivolumab (Opdivo®). The treatment will be determined randomly (by chance).

Download PDF

Download the information sheet for more information about this trial that you can show to your oncology team

Find out more
Bladder cancerHead and neck cancer
Clinical trial in patients with certain types of bladder cancer or cancer of the head and neck (LUMINOS-103)

LUMINOS-103 is for patients with either of these 2 types of cancer. The first few patients will receive lerapolturev alone. After the first few patients are treated, all patients will receive lerapolturev together with a checkpoint inhibitor that depends on the solid tumor cancer of interest.

Patients with bladder cancer that has spread to the muscle around the bladder (muscle-invasive bladder cancer) may be eligible if they are planning to have surgery to remove their bladder or if surgery is not possible and the cancer will be treated only with medicine.

Patients with certain cancers of the head and neck area may be eligible for this clinical trial if they are planning to have surgery to remove the cancer or if surgery is not possible and the cancer will be treated only with medicine.  

Download PDF

Download the information sheet for more information about this trial that you can show to your oncology team

Find out more
  1. Keytruda is a registered trademark of Merck, Sharp, and Dohme Corp, a subsidiary of Merck and Co., Inc.  Opdivo is a registered trademark of Bristol-Myers Squibb Company.